Avantor launches new Protein A Chromatography Resin – PROchievA – that provides supply chain flexibility and improves downstream purification performance for monoclonal antibodies (mAbs) production

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced a new recombinant Protein A affinity chromatography resin used to purify antibodies during mAbs production.

Avantor launches new Protein A Chromatography Resin – PROchievA – that provides supply chain flexibility and improves downstream purification performance for monoclonal antibodies (mAbs) productionHealthcare demand is increasing rapidly across most of the world, driven principally by aging populations, an increased prevalence of chronic diseases and improved access to healthcare. Monoclonal antibodies (mAbs) are proteins engineered to mimic or enhance the body's immune system. Biopharmaceutical manufacturers are pursuing ways to optimize the mAbs production process for increased efficiency, speed-to-market and cost reduction.

Protein A chromatography is a proven downstream purification step in manufacturing mAbs. Yet, there remains a need to reduce the total purification costs while improving purity and yield. The new Avantor® recombinant protein A resin addresses these challenges.  

Dr. Ger Brophy, Executive Vice President for Biopharma Production at Avantor, said:

Biopharmaceutical developers and manufacturers are urgently seeking new tools to drive more efficiency in their production processes. But they cannot compromise on quality standards as they work to provide powerful medicines to patients in a timely, safe and efficient manner."

In performance tests conducted against other best-in-class Protein A resins on the market today, Avantor's novel J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A resin demonstrated high performance and provided best-in-class purification in the critical Protein A affinity chromatography step of mAbs manufacturing. Avantor's resin is compatible with current manufacturing standards which ensures continuity in workflow processes and compliance protocols.

"Our resin provides customers with a best-in-class, high-performing alternative to existing purification technology, with the benefit of greater supply chain flexibility and security," added Dr. Brophy.

The BAKERBOND® PROchievA™ resin is manufactured at Avantor's Bridgewater Innovation Center in N.J., USA and is the company's latest example of driving improved bioprocessing efficiencies for the Life Sciences industry. Avantor recently teamed up with the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland to address downstream bottlenecks in buffer preparation when producing mAbs. More recently Avantor opened its ninth Innovation and Customer Support Center, which is located in Shanghai, China.  

The new resin enhances Avantor's J.T.Baker® family of products for biopharmaceutical research and production. Avantor's J.T.Baker® brand chromatography products allow biopharma manufacturers to realize higher production efficiencies, meet stringent regulatory requirements and accelerate regulatory approval in bringing new therapies to market.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Avantor. (2020, March 20). Avantor launches new Protein A Chromatography Resin – PROchievA – that provides supply chain flexibility and improves downstream purification performance for monoclonal antibodies (mAbs) production. News-Medical. Retrieved on October 01, 2020 from https://www.news-medical.net/news/20200320/Avantor-launches-new-Protein-A-Chromatography-Resin-PROchievA-that-provides-supply-chain-flexibility-and-improves-downstream-purification-performance-for-monoclonal-antibodies-(mAbs)-production.aspx.

  • MLA

    Avantor. "Avantor launches new Protein A Chromatography Resin – PROchievA – that provides supply chain flexibility and improves downstream purification performance for monoclonal antibodies (mAbs) production". News-Medical. 01 October 2020. <https://www.news-medical.net/news/20200320/Avantor-launches-new-Protein-A-Chromatography-Resin-PROchievA-that-provides-supply-chain-flexibility-and-improves-downstream-purification-performance-for-monoclonal-antibodies-(mAbs)-production.aspx>.

  • Chicago

    Avantor. "Avantor launches new Protein A Chromatography Resin – PROchievA – that provides supply chain flexibility and improves downstream purification performance for monoclonal antibodies (mAbs) production". News-Medical. https://www.news-medical.net/news/20200320/Avantor-launches-new-Protein-A-Chromatography-Resin-PROchievA-that-provides-supply-chain-flexibility-and-improves-downstream-purification-performance-for-monoclonal-antibodies-(mAbs)-production.aspx. (accessed October 01, 2020).

  • Harvard

    Avantor. 2020. Avantor launches new Protein A Chromatography Resin – PROchievA – that provides supply chain flexibility and improves downstream purification performance for monoclonal antibodies (mAbs) production. News-Medical, viewed 01 October 2020, https://www.news-medical.net/news/20200320/Avantor-launches-new-Protein-A-Chromatography-Resin-PROchievA-that-provides-supply-chain-flexibility-and-improves-downstream-purification-performance-for-monoclonal-antibodies-(mAbs)-production.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.